Behfar Ehdaie

Associate Professor Surgery @MSKCancerCenter | BA @UVA | MD @Georgetown | MPH @Harvard | Husband | Father | Mentor *Opinions expressed are my own*

[Behfar Ehdaie @BehfarEhdaieMD]

💥On behalf of co-investigators @claretempany @adamkibel_uro @qdtrinh and co-senior authors @geoffsonn Peji Ghanouni, we are excited to share the FINAL results of MR-guided HIFU Focal Therapy in men with intermediate risk prostate cancer. 1/8 https://t.co/deiCblMZPT

[Focal Therapy Society @FocalSociety]

This is what I'm talking about @ #AUA26: The masters at focal therapy discuss the finer points at the "Essentials in Prostate Cancer Focal Therapy" Course. The field is maturing and it great to see data driven decision making to optimize care for our pts with prostate cancer.

[Jim Hu @jimhumd]

@BehfarEhdaieMD Kicking off the @UrologyMSK focal therapy and targeted biopsy course @KoelisBx @FocalOneHIFU

[Samson W. Fine, MD @rovingatuscap]

Honored to join Urologic Oncology colleagues and lend a Pathology voice and insights to the proceedings of this meeting addressing Targeted Biopsy & Focal Therapy @BehfarEhdaieMD @MSKCancerCenter

[Dr Andre Abreu @ALDCAbreu]

🎯 Join us at @MSKCancerCenter for
Advanced Techniques in Target Prostate Biopsy & Focal Therapy in Prostate Cancer

Case-based interactive expert panels

📅 05/14/26 @ NYC 🗽🇺🇸

Perfect timing before heading to DC for #AUA2026 ✈️ 🚅

Free registration 🔗: https://t.co/7RVeEKZjd9

[Behfar Ehdaie @BehfarEhdaieMD]

@marthpodi @ChiUroSociety Thank you to the @ChiUroSociety for an engaging evening of multidisciplinary presentations and insightful discussion in an elegant setting. Dr Belfield was a true pioneer and giant in medicine.

[Behfar Ehdaie @BehfarEhdaieMD]

@dipenjparekh @gonzomdphd Congratulations 🙌. Richly deserved.

[Behfar Ehdaie @BehfarEhdaieMD]

Come join us for hopefully an engaging and balanced AUA Course reviewing key concepts in prostate cancer focal therapy. Distinguished faculty discuss their experience and reveal advanced techniques using all focal therapy technology in a lively case-based format #AUA25

[Dr Andre Abreu @ALDCAbreu]

The inaugural Masterclass in Robotic HIFU for Prostate Cancer is only one day away! We are excited to have focal therapy experts Pierre Halteh, MD, @AmirLebastchi, MD, @BehfarEhdaieMD and Pr. Sebastien Crouzet share their personal experience.
@USC_Urology @FocalOneHIFU

[Behfar Ehdaie @BehfarEhdaieMD]

@nyulangone @nyugrossman Congratulations Alec! Well deserved. #10538

[UrologyMSK @UrologyMSK]

Now in Clin Genitourin Cancer by @UrologyMSK @SigridCarlsson @vinlaudonemd @TouijerKarim @easthamja @BehfarEhdaieMD et al:
Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Grade Group 2 Prostate Cancer on Active Surveillance
https://t.co/IKqRXKsa0A

[Gladell Paner, MD @GladellPaner]

#GU Reporting Insights: #ProstateCancer Program

Covers: 1) prework talks (now available online) and 2) live-streamed webinar on Jan 22, 2025.

Please register and share! Big discounts for junior CAP members! #GUPath #Pathology
👇👇👇

https://t.co/Oil1mbhhms

[Colin Begg @ColinBBegg]

Is it possible to conduct large randomized surgical clinical trials in a single institution? The answer is yes, say Andrew Vickers and colleagues, reporting their experiences at Memorial Sloan Kettering. @SCTorg @VickersBiostat @MSKCancerCenter @MSKBiostats @BehfarEhdaieMD

[UroToday.com @urotoday]

#SUO24 #Debate – Management of localized radiorecurrent #ProstateCancer: Salvage radical prostatectomy. Presentation by @BehfarEhdaieMD @MSKCancerCenter. Written coverage by @zklaassen_md @GACancerCenter > https://t.co/7Fmg8oshy2 @UroOnc

[Behfar Ehdaie @BehfarEhdaieMD]

@jimhumd @seanmmcbride Some additional thoughts: most patients’ data classified as outcome failure are low vol GG2 (MR- invisible) in the opposite hemigland (not dx on initial bx); & patients have option to resume AS. We are preparing 5-yr tx failure data to provide more counseling info for physicians

[Behfar Ehdaie @BehfarEhdaieMD]

@uroegg Perfect is the enemy of good.

[Behfar Ehdaie @BehfarEhdaieMD]

@CGaffMD @MSKCancerCenter @eugene_pietzak @PCF_Science @UrologyCareFdn @UrologyMSK Congratulations! Well deserved; trailblazing collaboration between institutions and across departments. Looking forward to watching your career in academic urologic oncology launch.

[Behfar Ehdaie @BehfarEhdaieMD]

@seanmmcbride @HimanshuNagarMD @MSKCancerCenter Welcome to the team!! Excited to work together.

[Behfar Ehdaie @BehfarEhdaieMD]

Come join us for hopefully an engaging and balanced AUA Course reviewing the role of focal therapy in prostate cancer & translating the outcomes of clinical trials in clinical practice. Agnostic of technology but esteemed faculty discussing experience with all FT devices. #AUA24

[Behfar Ehdaie @BehfarEhdaieMD]

@ProtonStorey @DrSpratticus And, do these “reclassified” cancers detected with adv bx techniques impact oncologic outcomes. As you mentioned, rad onc prospective trials are reassuring. And, 10yr+ registry data in focal therapy also reporting >95% metastases free and >98% survival data @LondonProstate1

[Behfar Ehdaie @BehfarEhdaieMD]

@ProtonStorey @DrSpratticus Fair points Mark. We should continue to push and improve outcomes in this emerging treatment modality. Thought provoking: we observed 25% misclassification on initial bx (high vol, MR/Bx) -how many patients referred to radiation onc are undertreated based on biopsy tx planning?